New kit offers researchers and development teams a meaningful advance in expression speed and output

BOSTON, May 12, 2026 /PRNewswire/ -- GenScript Biotech Corporation announced the launch of TurboCHO™ Protein Expression Kit, a next-generation antibody expression reagent designed to set a new benchmark for speed, performance, output and ease-of-use. One of the company's largest global product launches to date, this kit targets the fast-growing expression reagent market, driven by high-throughput and AI-enabled research.

Producing research-grade antibodies and proteins is a foundational step in drug discovery and biologics development. The new kit brings GenScript's proven protein-expression technology directly to the bench in a ready-to-use format, enabling labs of any size to generate high‑quality protein in as little as five business days. As a result, researchers can access reliable data sooner and make earlier, more confident decisions.

"TurboCHO™ Protein Expression Kit delivers outstanding performance and unmatched value, putting powerful innovation within reach of every lab working to advance science," said GenScript's Rotating CEO Sherry Shao. "By providing a launchpad to market, this kit helps bring new medicines to patients' faster, when time matters most."

The product debuted yesterday at the opening of the PEGS Summit in Boston, but attendees will have opportunities throughout the week to learn more and engage with the GenScript team. The Protein Expression Kit is available in two configurations:

• Pro: Delivers high-yield protein expression in as little as 5 business days, designed for easy integration into existing workflows.
• Prime (Licensed): Enhanced performance for teams seeking maximum speed, with results as early as Day 3 and even higher yields.

Early Feedback Supports Real-World Impact

Early adopters in the beta program have reported performance that is "best in class" for speed and value, demonstrating its real-world impact.

_________________________________________________________________________________

Performance Snapshot: How the Kit Compares

• Redefines expression speed, providing Day 5 yields (or Day 3 for Prime) comparable to competitor Day 10 results, substantially shortening timelines and accelerating decision-making
• Delivers higher yields with lower reagent input, improving overall cost efficiency and throughput
• Produces up to three-fold higher yield (or 5-fold for Prime) after Protein A purification versus other market solutions
• Features a proprietary high‑performing cell line and optimized transfection system

_________________________________________________________________________________

For drug developers and research teams managing increasingly compressed discovery timelines, this performance translates into faster candidate selection, reduced time-to-data, and the capacity to validate more candidates as they move into experimental testing.

The launch represents the first phase of a broader innovation roadmap designed to drive continued industry leadership, with planned advances spanning next‑generation CHO cell line enhancements, improved transfection systems, and scalable, automation‑ready formats.

"By delivering higher-quality antibody expression with dramatically faster time-to-data, we are eliminating a critical bottleneck in drug discovery," said Ray Chen, President of GenScript Life Science Group. "Designed for today's complex molecules, this kit ensures reproducibility and seamless screen-to-scale translation, while enabling more designs to be tested at lower cost. For research teams working under aggressive discovery timelines, the real question isn't whether to adopt this solution. It's how quickly they choose to leverage it to redefine what's possible."

TurboCHO™ Protein Expression Kit is available immediately through GenScript's direct sales channels and authorized distributors. To support early adoption, GenScript is offering introductory pricing for a limited time, along with technical support for onboarding and workflow optimization. Inventory is in place to support both domestic and international demand. For more information or pricing, visit the GenScript website.  

About GenScript

Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners—from academic institutions to industry leaders—to co-create cutting-edge solutions that redefine service excellence. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 6,100+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world's Top 20 pharma companies. For more information: www.genscript.com

Media Contacts:

Kate Grusich

Senior Corporate Communications Manager

Katherina.Grusich@genscript.com 

Photo - https://mma.prnewswire.com/media/2977421/Picture1_launchpad.jpg

Photo - https://mma.prnewswire.com/media/2978147/PEGS_Summit.jpg

Logo - https://mma.prnewswire.com/media/2855189/GenScript_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/genscript-launches-turbocho-protein-expression-kit-delivering-the-fastest-path-to-antibodies-in-its-class-302769842.html

Sandoz hat im ersten Quartal 2026 trotz erheblicher Verwerfungen im Penicillin-Geschäft weiteres Wachstum erzielt. Der Umsatz des Schweizer Generika- und Biosimilar-Spezialisten belief sich zwischen Januar und März auf 2,76 Milliarden US-Dollar, ein Plus von 11 Prozent gegenüber dem Vorjahreszeitraum. Zu konstanten Wechselkursen legten die Erlöse um 3 Prozent zu. Der Konzern bestätigt nach eigenen Angaben seinen Ausblick für das Gesamtjahr.

Treiber der Entwicklung war vor allem das höhermargige Biosimilar-Geschäft, das die frühere Novartis-Tochter weiter ausgebaut hat. Dagegen stand die grössere Generika-Sparte erneut unter Druck, weil sich die Marktverwerfungen im Penicillin-Segment fortsetzten. Klammerte man die negativen Auswirkungen aus dem Antibiotika-Geschäft aus, hätte das Umsatzplus zu konstanten Wechselkursen bei rund 5 Prozent gelegen und damit im Rahmen der Unternehmensprognose.

Die Belastungen resultieren aus einem anhaltenden Preisverfall bei wichtigen Penicillin-Wirkstoffen (Active Pharmaceutical Ingredients), der bereits im Vorjahr eingesetzt hatte. Hintergrund sind US-Zölle, die chinesische Anbieter dazu veranlasst haben, ihre Penicillin-Mengen verstärkt nach Europa umzuleiten. Das zusätzliche Angebot hat dort die Preise deutlich gedrückt. Parallel dazu führten in Indien eingeführte Mindestpreisvorschriften dazu, dass weniger chinesische Ware in diesen Markt floss, was den Wettbewerbsdruck in Europa zusätzlich verschärfte und den Preisdruck weiter verstärkte.

Laut Sandoz konzentrieren sich die heftigsten Auswirkungen dieser Entwicklung auf das erste Quartal, die verbleibenden Effekte sollen sich nun schrittweise abschwächen. Analysten verweisen darauf, dass das Unternehmen ohne den Antibiotika-Gegenwind im Rahmen seiner Guidance gewachsen wäre. Der Konzern bleibt damit auf Wachstumskurs, muss sich im Generika-Kerngeschäft jedoch weiterhin in einem von handelspolitischen Eingriffen und regulatorischen Änderungen verzerrten Marktumfeld behaupten.